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Purpose or Objective: The prognosis of oesophageal cancer 
(OC) is poor, with overall 5-year survival approximately 15%. 
The presence of lymph node metastases (LNMs) is a major 
prognostic indicator and the ability to identify LNMs is 
important. Texture analysis of medical images enables 
additional information to be extracted from routine staging 
investigations and quantifies intra-tumoural characteristics 
via non-invasive methods. The aim of the study is to obtain 
preliminary data investigating the association of texture 
variables and LNMs. 
 
Material and Methods: A prospectively maintained database 
including clinical, radiological and pathological details of 
consecutive OC patients with biopsy proven adenocarcinoma 
in South East Wales from October 2010 to August 2013 was 
retrospectively analysed. All patients underwent PET/CT 
staging. Consecutive patients were grouped into those with 
and without LNMs on endoscopic ultrasound (EUS), considered 
the superior staging investigation for loco-regional 
assessment. Texture analysis of the primary tumour was 
carried out on the PET images using PET-STAT, software 
developed and written in the Matlab-based open source 
software CERR. The tumour was outlined with ATLAAS, a 
learning algorithm for optimised automatic segmentation 
developed at Cardiff University. Seventeen variables 
including SUVmax, metabolic tumour volume (MTV), total 
lesion glycolysis (TLG) and intensity variability (IV) were 
calculated. Table 1 details all variables calculated. Patients 
with primary tumour volume less than 5 ml and distant 
metastatic disease were excluded. Independent T-tests were 
used to identify promising texture variables for future study. 
A p-value <0.05 was considered significant. Primary outcome 
was LNMs on EUS. 
 
Results: Eighty-one patients underwent staging with PET/CT 
and EUS [male 67, median age 66 (range 42-82)]. Forty 
patients were staged as N0 on EUS, with 41 having evidence 
of regional lymph node metastases. Independent T-tests 
demonstrated significant differences between patients with 
and without LNMs for MTV [mean 38.45 v 21.71; t(56.03)=-
2.449, p=0.017], TLG [mean 328.72 v 208.66; t(74.721)=-
2.023, p=0.047], Coarseness [mean 0.010 v 0.013; 
t(79)=3.107, p=0.003], Entropy [mean 6.15 v 5.91; t(79)=-
2.075, p=0.041] and IV [mean 21.09 v 13.45; t(64.366)=-
2.458, p=0.017]. 
 
Conclusion: Preliminary results have shown a number of 
texture variables that have the potential to predict LNMs. 
On-going work at our institution is investigating the added 
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Purpose or Objective: Perioperative chemotherapy (pCT) 
and neoadjuvant chemoradiotherapy (nCRT) are well-
established therapies to improve survival for resectable non-
metastatic esophageal carcinoma. However, the optimal type 
of treatment for esophageal adenocarcinoma is currently 
under debate. Until now, limited evidence is available to 
determine whether pCT or nCRT is most beneficial with 
regard to toxicity, pathologic outcome and survival. 
Therefore, the aim of this study was to compare toxicity, 
pathologic outcome and survival after pCT versus nCRT and 
surgery in patients with esophageal adenocarcinoma. 
 
Material and Methods: Consecutive patients who underwent 
pCT or nCRT followed by esophagectomy for cancer between 
October 2006 and September 2015 in a single institution were 
analyzed. The pCT regimen consisted of intravenous 
administration of epirubicin, cisplatin and capecitabin, 
whereas nCRT consisted of paclitaxel and carboplatin with 
concurrent radiotherapy. Toxicity of grade 3 or higher was 
scored according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events. Data on surgical 
procedures, complications and follow-up were collected from 
a prospectively maintained database. Full propensity score-
matching was applied to generate matched sets of cases 
based on pretreatment covariates in order to create 
comparable groups. Univariable analysis was performed to 
determine differences between the two groups. Disease-free 
survival (DFS) and overall survival (OS) were assessed using 
the Kaplan-Meier method and log-rank test. 
 
Results: A total of 189 eligible patients were identified of 
whom 19 were discarded after propensity matching; 86 
underwent pCT and 84 received nCRT. During preoperative 
therapy, thromboembolic events occurred more frequently in 
the pCT group (18% vs. 0%, p<0.001), while leukopenia 
occurred more frequently in the nCRT group (25 vs. 11%, 
p=0.013). Complete resection with no tumor within 1 mm of 
the resection margins (R0) was achieved in 90% of patients in 
the pCT group, as opposed to 96% in the nCRT group 
(p=0.103). Pathologic tumor regression was more frequently 
observed in patients who underwent nCRT compared to pCT 
(p<0.001). There was no significant difference between the 
groups with regard to risk of surgical complications, length of 
hospital stay or in-hospital mortality. Both treatments 
resulted in comparable 3-year DFS (49% vs. 53% for pCT and 
nCRT, respectively, log-rank p=0.774) and OS rates (48% vs. 
51%, log-rank p=0.842) (Figure 1). 
 
 
Conclusion: Perioperative chemotherapy (MAGIC) and 
neoadjuvant chemoradiotherapy (CROSS) were associated 
with comparable toxicity and postoperative morbidity. 
Although neoadjuvant chemoradiotherapy was associated 
with improved tumor regression compared to perioperative 
chemotherapy, this finding did not translate into improved R0 
resection or 3-year survival rates. 
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Purpose or Objective: To evaluate the patterns of 
recurrence and its value in target delineation for 
postoperative radiotherapy(PORT) in patients with stage III 
thoracic esophageal squmous cell carcinoma(ESCC) after 
esophagectomy. 
 
Material and Methods: 395 patients with stage III thoracic 
ESCC treated with radical esophagectomy from Jan, 2008 to 
Dec, 2011 were enrolled in this study. No patients has 
accepted preoperative adjuvant therapy. There were 302 
males and 93 females; median ages was 60 years old (range 
33-83). There were 33 patients located in upper-, 273 in 
middle- and 89 in low-segment. 375 patents has operated 
with two-field and 22 with three-field esophagectomy. The 
median number of dissected lymph nodes were 10 per case 
(range 1-34). There were 244 with stage IIIA, 106 with IIIB 
and 45 with IIIC. There were 97 patients received with 
surgery alone, 212 with postoperative chemotherapy(POCT), 
86 with PORT(30 with POCT and PORT). Diagnosis of 
recurrence was parimarily based on CT images, some of 
which were biopsy-confirmed. The location and time of 
tumor recurrences were analyzed. 
 
Results: The overall failure rates was 75.7%(299/395). 
Locoregional recurrence(LR) was found in 48.4% of patients, 
distant metastasis(DM) in 16.2%, and LR plus DM in 4.3%; the 
total rate of LR and DM were 52.7% and 20.5%, respectively. 
There were 208 patients recurred with LR, 26.9%(56) 
recurred in supraclavicular/neck(51 in supraclavicular), 69.7% 
(145) in mediastinum, and 19.7% (41) in upper abdomen (38 
in para-aortic lymph node). 92.8% of LR involved locoregional 
lymph nodes; the rate of anastomotic recurrence was 5.1% 
(20/395). Further analysis showed that upper-mediastinal 
recurrence accounted for 88.7% of mediastinal recurrence. 
The estimated 1-, 3-, and 5-year accumulated LR rates for all 
patients were 32.2%, 55.1% and 60.1%. Multivariate COX and 
logistic regression analysis showed that TNM stage and 
adjuvant therapy were independent factor for LR (p<0.05); 
PORT could reduce LR, especially in patients with middle-
thoracic segment, IIIA and IIIB disease, two-field 
esophagectomy, less than 6 dissected lymph node or severe 
adhesion at surgery (p<0.05); but POCT did not decrease LR. 
 
Conclusion: The recurrence rate was very high in stage III 
thoracic ESCC patients, LR was the main pattern of failure; 
TNM stage was one of the most important factor for LR. PORT 
could reduce LR but POCT could not. Upper-mediastinum was 
the most common site of recurrence, followed by 
supraclavicular and para-aortic regions; these areas should be 
consedered the key target of PORT. 
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Purpose or Objective: Aim of this study is the evaluation of 
feasibility and efficacy of SBRT in the treatment of 
unresectable hepatocellular carcinoma (HCC). 
 
Material and Methods: Patients with 1-3 inoperable HCC 
lesions with diameter ≤6cm were treated by SBRT. 
Prescription dose was 36-75Gy in 3-6 fractions. SBRT was 
delivered using the volumetric modulated arc therapy 
technique with flattening filter free photon beams. The 
primary end points of this study were in–field local control 
(LC) and toxicity. Secondary end points were overall survival 
(OS) and progression free survival (PFS). 
 
Results: From February 2011 and April 2015, 71 patients with 
102 HCC lesions were irradiated. All patients had Child-
Turcotte-Pugh class A or B disease. Median follow-up was 9 
months (range 5-43 months). Actuarial LC at 1 and 2-years 
was 92% and 81%. An Equivalent Dose >100Gy was a 
significant prognostic factor for LC in univariate analysis, 
with a 1-2 years LC rates of 99%-94% for a subgroup of lesions 
treated with a BED ≥100Gy and 58% -29% for lesions treated 
with a BED <100Gy (p<0.001). Median OS was 25 months. 
Actuarial OS at 1 and 2 years was 70% and 60%, respectively. 
Univariate analysis showed that OS is correlated with LC 
(p<0.02), BED>100 (p<0.05) and Cumulative GTV<5cm 
(p<0.04). Median PFS was 9 months. Grade ≥3 toxicity was 
observed in 7 patients (18%). No classic RILD was observed. 
 
Conclusion: Our study shows that SBRT is a safe and effective 
treatment for selected patients with inoperable HCC. Local 
control rates and toxicity profile were encouraging. 
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Purpose or Objective: In the TNM 7 staging, supraclavicular 
lymph nodes (SCN) are considered distant metastasis and thus 
prognostically unfavourable. This is one of the reasons for a 
generally accepted policy to treat these patients with 
supraclavicular disease spread and without further distant 
metastases with definitive chemoradiation (dCRT), 
irrespective of N stage. However, the worse prognostic value 
of a supraclavicular disease may be questioned. We analysed 
the prognostic value of supraclavicular disease in dCRT for 
esophageal cancer. 
 
Material and Methods: We retrospectively analyzed 207 
patients treated between 2003 and 2013 with a standardized 
protocol of definitive chemoradiation (dCRT) for esophageal 
cancer to identify the prognostic value of metastasis in the 
supraclavicular lymphnodes on treatment failure and 
survival, with special attention to the relation between 
supraclavicular disease and N stage. All patients were treated 
with external beam radiotherapy (50.4 Gy in 28 fractions) 
combined with weekly concurrent paclitaxel 50 mg/m2and 
carboplatin AUC2. 
 
Results: Median follow up time for patients alive was 43.3 
months The median overall survival (OS) for all patients was 
17.5 months. OS at 1, 3 and 5 year was 67%, 36.1% and 21.3% 
respectively. For patients with a metastasis in a 
supraclavicular lymph node, overall survival was 23.6 months 
compared to 17.1 months for patients without a metastasis in 
the SCN (p=0.51). In multivariate analyses , higher cT status, 
cNstatus and tumor length were found prognostically 
unfavorable, but a positive supraclavicular lymph node was 
not of independent prognostic value for survival (p=0.67). 
The relationship between SCN involvement and N stage was 
analyzed separately. Median OS for tumors with SCN 
involvement and N0/1 disease was 49.0 months (15.4-82.6) 
compared to 17.4 months in patients with N2/3 disease 
(95%CI 99-24.8 p=0.097). Median diseasefree survival (DFS) 
for tumors with SCN involvement and N0/1 disease was 51.6 
months (95%CI 0-108.5) compared to 8.2 months in the N2/3 
group (95%CI 6.2-10.1 p=0.028). No significant difference in 
